Dr. Janku on Longitudinal Monitoring of BRAF V600E Mutation in Urinary Cell-Free DNA

Video

Filip Janku, MD, PhD, discusses longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers.

Filip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, discusses longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers. This study was presented at the 2014 ASCO Annual Meeting.

While BRAF mutation status changes over time, constantly biopsying patients is not feasible for a number of reasons. There remains a need for an alternative source of mutational analysis that can work over time.

The purpose of this study was to monitor the amount of BRAF mutation in a patient’s plasma and use it as a surrogate for response to therapy.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center